Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.

Cancer chemotherapy and pharmacology - 1 Aug 2011

Chang Myung Hee, Lee In Kyu, Si Yoon, Lee Kyu Sang, Woo In-Sook, Byun Jae Ho

Abstract excerpt

BACKGROUND: K-ras proto-oncogene is commonly mutated in colorectal cancer (CRC) and has been associated with predictive markers for anti-EGFR (epidermal growth factor receptor) therapy. However, the prognostic role of K-ras status is still unclear. The aim of this study was to evaluate the association between k-ras status and addition of oxaliplatin to fluorouracil plus leucovorin (FOLFOX) chemotherapy in CRC...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fluorouracil

Share to Genes, ras

Share to Leucovorin

Share to Organoplatinum Compounds

Share to Oxaliplatin

Share to Proto-Oncogene Mas

Source

Identifiers

PMID: 20972872
DOI: 10.1007/s00280-010-1496-5

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.PMID 20972872Read ↗

KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.Semantic proximity Read ↗

K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy.Semantic proximity Read ↗

Is K-ras Gene Mutation a Prognostic Factor for Colorectal CancerSemantic proximity Read ↗

Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients.Semantic proximity Read ↗

K-ras mutations in colorectal cancer: a practice changing discovery.Semantic proximity Read ↗

The type of K-ras mutation determines prognosis in colorectal cancer.Semantic proximity Read ↗

Mutations in codons 12 and 13 of K-ras exon 2 in colorectal tumors of Saudi Arabian patients: frequency, clincopathological associations, and clinical outcomes.Semantic proximity Read ↗

Can K-ras gene mutation be utilized as prognostic biomarker for colorectal cancer patients receiving chemotherapy? A meta-analysis and systematic review.Semantic proximity Read ↗

K-Ras mutation and prognosis of colorectal cancer: a meta-analysis.Semantic proximity Read ↗

Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy.Semantic proximity Read ↗

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.Semantic proximity Read ↗

KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.